SCHEMBL23978109

SCHEMBL23978109

COc1ccc(Nc2nc(Cl)ncc2CNc2c(CF)csc2Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKA O14965 2/20 0.38
SYK P43405 1/20 0.38
MAPT P10636 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALOX5 P09917 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
EGFR P00533 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
KCNH3 Q9ULD8 1/20 0.34
PTGS2 P35354 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309538 1.00 AURKA (0.38) AURKASYKMAPTSMN1; SMN2ALOX5
SCHEMBL23978127 0.89 TRPV4 (0.35) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL30309532 0.89 TRPV4 (0.35) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL30309515 0.81 ALDH1A1 (0.32) ALDH1A1
SCHEMBL23978096 0.81 ALDH1A1 (0.32) ALDH1A1
SCHEMBL23978367 0.80 MAPK1 (0.32) CYP1A2CYP3A4CYP2C19KMT2ANPC1
SCHEMBL30309547 0.77 TRPV4 (0.38) SMN1; SMN2CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL23978116 0.77 TRPV4 (0.38) SMN1; SMN2CYP1A2CYP3A4CYP2C19MEN1
SCHEMBL23978094 0.76
SCHEMBL23978385 0.76 TRPV4 (0.34) ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2023-06-22 US disclosed
WO-2021219731-A2 BICYCLIC KINASE INHIBITORS AND USES THEREOF IOMX THERAPEUTICS AG (DE) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192701-A1 BICYCLIC KINASE INHIBITORS AND USES THEREOF MITF, PRKDC, PRKACA AURKA 232/4885SYK 1354/4885MAPT 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.